Ten stocks mirrored a lackluster performance in the broader market on Tuesday, posting hefty double-digit losses primarily due to disappointing earnings performance and a lower growth outlook for the ...

Hims & Hers Health shares fell 12% in after-hours trading on Monday after the telehealth company missed second-quarter ...

The telehealth company posted revenue of $544.8 million in the second quarter, marking a 73% increase year over year but missing analyst estimates for $552 million, according to Bloomberg data. Hims & ...

Hims & Hers Health Inc (HIMS) reports a 73% revenue surge and strategic acquisitions, while navigating challenges in cash ...

Stay updated on Hims & Hers Health Q2 2025 earnings: subscriber growth, global expansion, & personalized care innovation.

The company has big ambitions. It wants to reach at least $6.5 billion in sales by 2030. In the short term, as it tries to steer its consumers to high-end daily products, Chief Financial Officer Yemi ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Hims & Hers Health, a telehealth platform that sells knock offs of popular weight loss drugs, sank in after-hours trading ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Shares of Hims Hers Health Inc (NYSE:HIMS) fell more than 3% early Tuesday before paring losses to around 0.2% in afternoon trade, after rising legal risks and a data disclosure drove swings in ...

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...